PT-141 10mg/vial 1 Vial by Knoll Pharmaceuticals

Usage

1. Reconstitute the vial: draw 1–2 mL of bacteriostatic water into a 29–31 gauge insulin syringe and inject it slowly down the inside wall of the PT-141 vial; swirl gently for 30 seconds until the lyophilised cake fully dissolves — never shake.
2. Calculate your dose volume: divide the total mg dissolved by the volume added (e.g. 10 mg in 2 mL = 5 mg/mL), then draw the volume matching your target dose (0.5 mg = 0.1 mL at this concentration).
3. Choose an injection site appropriate for subcutaneous delivery — lower abdomen (at least 2 cm from the navel) or outer thigh are preferred; rotate sites with each administration to prevent tissue irritation.
4. Clean the skin with an alcohol swab and allow it to dry completely; pinch a fold of skin, insert the needle at a 45-degree angle, aspirate briefly, and inject the solution slowly over 5–10 seconds.
5. Time your dose correctly: administer PT-141 approximately 45–60 minutes before anticipated sexual activity to align peak plasma concentration with the intended effect window.
6. After use, cap and dispose of the syringe in a sharps container; re-stopper the vial and return it to the refrigerator (2–8 °C); label with the reconstitution date and discard any remaining solution after 28 days.

Warnings

Frequently asked questions

How does PT-141 (Bremelanotide) work in the brain to increase libido?

PT-141 activates melanocortin receptor subtypes MC3R and MC4R in the hypothalamus, triggering downstream dopaminergic signalling along the mesolimbic reward pathway. This cascade generates the neurochemical conditions for sexual desire and arousal at a central level — before any peripheral vascular event occurs. Because the mechanism is central rather than vascular, it works independently of testosterone levels or blood-flow status.

Does PT-141 work for women as well as for men?

Yes — clinical trial data submitted for the FDA-approved bremelanotide product (Vyleesi) confirmed efficacy in pre-menopausal women with hypoactive sexual desire disorder. Women using PT-141 report increased genital sensitivity and greater subjective arousal. Men benefit from improved erection quality and heightened motivation. The shared hypothalamic MC4R target accounts for comparable outcomes across sexes.

How long before sexual activity should PT-141 be injected?

PT-141 should be administered subcutaneously approximately 45–60 minutes before anticipated sexual activity. Plasma concentrations peak within this window and the compound's half-life of roughly 2.7 hours sustains the effect for several hours. Injecting earlier than 90 minutes or later than 30 minutes before activity may reduce the quality of the response timing.

How do you reconstitute and store a PT-141 10mg/vial after opening?

Add 1–2 mL of bacteriostatic water to the lyophilised powder using a sterile insulin syringe; swirl gently — do not shake — until fully dissolved. Once reconstituted, store the vial upright in a refrigerator at 2–8 °C and use within 28 days. Draw individual doses with a fresh insulin syringe each time, wiping the rubber stopper with an alcohol swab before each draw.

What syringe type and injection site are recommended for PT-141 dosing?

A 29–31 gauge, 0.5-inch insulin syringe is the standard choice for subcutaneous PT-141 administration. Common injection sites include the lower abdomen or outer thigh, rotating each time to minimise local irritation. Pinch the skin lightly, insert at a 45-degree angle, inject slowly, and withdraw. The small gauge minimises discomfort given the low injection volume (typically 0.1–0.4 mL per dose). (2) angle_used

Manufacturer

Knoll Pharmaceuticals' PT-141 10 mg/vial product reaches distribution only after each production batch passes through a structured two-stage quality-release sequence — both stages are mandatory, analytically independent, and address entirely separate risk categories. The sequence opens with identity and purity characterisation: the bulk Bremelanotide active pharmaceutical ingredient undergoes HPLC (High-Performance Liquid Chromatography) analysis, with each batch's chromatographic trace benchmarked against a Bremelanotide-specific cyclic heptapeptide reference standard; any deviation in sequence identity or purity below the defined acceptance threshold results in immediate batch rejection prior to fill-and-finish operations. The second stage shifts focus from chemical purity to biological safety: a Limulus Amebocyte Lysate (LAL) endotoxin assay is applied to the filled, lyophilised vials to confirm that bacterial endotoxin levels remain below the threshold for injectable peptide products. Both gates are executed within a current Good Manufacturing Practice (cGMP) framework, and batch-release documentation from each stage is retained as a permanent record. A vial that has not cleared both checkpoints does not leave the facility.